I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination

N/AActive Not RecruitingNCT04452526

Ohio State University Comprehensive Cancer Center372 enrolled

Overview

This trial studies how well a multi-level health system-based intervention works in improving human papillomavirus (HPV) vaccine initiation and completion among children in health systems in four Appalachian states. Utilizing educational and promotional materials and electronic health record reminders, may improve the uptake of the HPV vaccine in children and young adults, ultimately preventing the development of cervical cancer.

PRIMARY OBJECTIVE: I. Test the effectiveness of a multi-level intervention (MLI) directed at clinics, providers, and patients (parents of children aged 11-12) to improve HPV vaccine initiation and completion in health systems in four Appalachian states (Kentucky \[KY\], Ohio \[OH\], West Virginia \[WV,\] and Virginia \[VA\]) among children aged 11-12 and assess the effectiveness of the intervention program among subgroups, e.g., females versus (vs) males. SECONDARY OBJECTIVES: I. Assess sustainability of the intervention. II. Assess cost impacts of the intervention III. Assess changes in clinic practices that occur as a result of the intervention in terms of staff responsibilities for the vaccination process and reducing missed opportunities for vaccination. IV. Assess whether interventions focused on 13-26 year olds increases catch-up vaccination. V. Examine changes in knowledge and attitudes of providers via educational session pre-post surveys. VI. Satisfaction with the intervention at the multiple levels. OUTLINE: Health systems are randomized to 1 of 2 arms. ARM I (EARLY INTERVENTION): Health systems receive educational materials consisting of posters, brochures and table tents. Providers complete survey about HPV knowledge, participate in educational session over 1 hour and receive educational handouts on the HPV vaccine. Patients receive educational materials about HPV vaccine and reminder letters for HPV vaccination. ARM II (DELAYED INTERVENTION): Health systems, providers, and patients receive usual care for 12 months, then receive multi-level intervention as in Arm I.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Conditions

Cervical Carcinoma Human Papillomavirus-Related Malignant Neoplasm

Interventions

Best PracticeOTHER

Receive usual care

Educational InterventionOTHER

Receive educational materials

Questionnaire AdministrationOTHER

Ancillary studies

Reminder

Eligibility

Sex: ALLMin age: 11 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: CLINIC * Located in one of the counties that are part of this program * Provides care to patients aged 11-26 * Provides immunizations HEALTH CARE PROVIDERS (PHYSICIANS, NURSES) AND OFFICE STAFF * Practicing in a clinic in one of the participating health systems * Personnel involved in the vaccine process (determined by individual clinics) * Able to speak, read, and write English

Locations (4)

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, United States

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

University of Virginia

Charlottesville, Virginia, United States

West Virginia University

Morgantown, West Virginia, United States

Outcomes

Primary Outcomes

Change in rate of human papillomavirus (HPV) vaccination initiation among 11-12 year olds

The effectiveness of the intervention will be assessed by comparing early vs delayed intervention clinics at the end of the first implementation phase adjusting for baseline rates and pre- versus (vs) post implementation rates in the delayed implementation clinics.

Time frame: Baseline up to 24 months

Change in rate of HPV vaccination initiation among those 13-26

Time frame: Baseline up to 24 months

Sustainability

Will use logistic regression models with random health systems effects to compare odds of vaccination at the end of sustainability period to odds of vaccination at the end of the implementation period.

Time frame: Up to 24 months

Cost-effectiveness

Will conduct the cost-effectiveness analyses of using the multi-level intervention (MLI) intervention to promote HPV vaccination in three broad steps.

Time frame: Up to 60 months

Change in knowledge of providers

Will compare changes in knowledge of providers via educational session pre-post survey. Changes in Knowledge following the educational session will be assessed using linear mixed models containing random health system effects.

Time frame: Baseline up to 60 months

Change in attitudes of providers

Will compare changes in attitudes of providers via educational session pre-post survey.

Time frame: Baseline up to 60 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.